EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Traws Pharma's enterprise value is $-8.65 Mil.
Traws Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $0.23 Mil. Therefore, Traws Pharma's EV-to-Revenue for today is -38.10.
The historical rank and industry rank for Traws Pharma's EV-to-Revenue or its related term are showing as below:
TRAW'
s EV-to-Revenue Range Over the Past 10 Years
Min: -128.77 Med: -0.69 Max: 1228.82
Current: -38.1
During the past 13 years, the highest EV-to-Revenue of Traws Pharma was 1228.82. The lowest was -128.77. And the median was -0.69.
TRAW's EV-to-Revenue is ranked better than 98.39% of 994
companies
in the Biotechnology industry
Industry Median: 7.16
vs TRAW: -38.10
As of today (2025-05-24), Traws Pharma's stock price is $1.31.
Traws Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $0.14. Therefore, Traws Pharma's PS Ratio for today is 9.49.
Traws Pharma EV-to-Revenue Historical Data
The historical data trend for Traws Pharma's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Traws Pharma's EV-to-Revenue
For the Biotechnology subindustry, Traws Pharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Traws Pharma's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Traws Pharma's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Traws Pharma's EV-to-Revenue falls into.
Traws Pharma's current Enterprise Value is $-8.65 Mil.
Traws Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.23 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Traws Pharma's share price for today is $1.31.
Traws Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.14.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Traws Pharma EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Traws Pharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TRAW has been successfully added to your 